Literatur
Schlögl H et al (2013) Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 36:1933–1940
Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C (1997) Distribution of glucagon-like peptide-1 and other preproglucagonderived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257–270
Hunter K, Holscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33
Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439
Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ (2014) Neuronal GLP1R mediates liraglutide s anorectic but not glucose-lowering effect. J Clin Invest 124:2456–2463
Heppner KM, Kirigiti M, Secher A et al (2015) Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156:255–267
Wang XF, Liu JJ, Xia J, Liu J, Mirabella V, Pang ZP (2015) Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons. Cell Rep 12:726–733
Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1129
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Jecht gibt an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Jecht, M. Auswirkungen von Liraglutid auf die Hirnaktivität. Diabetologe 12, 428–429 (2016). https://doi.org/10.1007/s11428-016-0133-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11428-016-0133-2